BLFS BIOLIFE SOLUTIONS INC

Nasdaq biolifesolutions.com


$ 27.69 $ -0.18 (-0.65 %)    

Tuesday, 21-Oct-2025 15:59:53 EDT
QQQ $ 610.29 $ -0.16 (-0.03 %)
DIA $ 469.10 $ 2.20 (0.47 %)
SPY $ 670.98 $ -0.01 (0 %)
TLT $ 91.99 $ 0.45 (0.49 %)
GLD $ 376.61 $ -25.91 (-6.43 %)
$ 27.68
$ 27.92
$ 21.00 x 100
$ 29.32 x 1
$ 27.66 - $ 28.56
$ 19.10 - $ 29.55
177,792
na
1.33B
$ 2.04
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-03-2025 01-01-1970 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-09-2024 06-30-2024 10-Q
6 05-10-2024 03-31-2024 10-Q
7 02-29-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-31-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-31-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-16-2021 06-30-2021 10-Q
18 05-17-2021 03-31-2021 10-Q
19 03-31-2021 12-31-2020 10-K
20 11-09-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-29-2020 03-31-2020 10-Q
23 05-15-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-09-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 03-15-2019 12-31-2018 10-K
28 11-08-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-11-2018 03-31-2018 10-Q
31 03-09-2018 12-31-2017 10-K
32 11-09-2017 09-30-2017 10-Q
33 08-11-2017 06-30-2017 10-Q
34 05-12-2017 03-31-2017 10-Q
35 03-15-2017 12-31-2016 10-K
36 11-10-2016 09-30-2016 10-Q
37 08-11-2016 06-30-2016 10-Q
38 05-16-2016 03-31-2016 10-Q
39 02-25-2016 12-31-2015 10-K
40 11-12-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 biolife-solutions-sells-cold-chain-logistics-subsidiary-savsu-cleo-technologies-for-255m-in-cash-to-peli-biothermal

BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell pr...

 hc-wainwright--co-maintains-buy-on-biolife-solutions-raises-price-target-to-32

HC Wainwright & Co. analyst Yi Chen maintains BioLife Solutions (NASDAQ:BLFS) with a Buy and raises the price target fro...

 biolife-solutions-raises-fy2025-sales-guidance-from-95500m-99000m-to-100000m-103000m-vs-97747m-est

BioLife Solutions (NASDAQ:BLFS) raises FY2025 sales outlook from $95.500 million-$99.000 million to $100.000 million-$103.000 m...

 biolife-solns-q2-adj-eps-001-beats-004-estimate-sales-25421m-beat-23710m-estimate

BioLife Solns (NASDAQ:BLFS) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.04)...

 biolife-solutions-announces-2m-investment-in-pluristyx

BioLife Solutions, Inc. (NASDAQ:BLFS), a leading developer and supplier of bioproduction products and services for the cell and...

 hc-wainwright--co-reiterates-buy-on-biolife-solutions-maintains-30-price-target

HC Wainwright & Co. analyst Yi Chen reiterates BioLife Solutions (NASDAQ:BLFS) with a Buy and maintains $30 price target.

 biolife-solutions-affirms-fy2025-sales-guidance-of-9550m-9900m-vs-9703m-est

BioLife Solutions (NASDAQ:BLFS) affirms FY2025 sales outlook from $95.50 million-$99.00 million to $95.50 million-$99.00 millio...

 biolife-solutions-acquires-90-of-panthera-cryosolutions-common-shares-it-does-not-down-for-93m-in-cash-and-241355-shares-of-biolife-stock

Strategic acquisition enhances biopreservation media portfolio with novel Ice Recrystallization Inhibitor technologyMarks the s...

 hc-wainwright--co-maintains-buy-on-biolife-solutions-raises-price-target-to-30

HC Wainwright & Co. analyst Yi Chen maintains BioLife Solutions (NASDAQ:BLFS) with a Buy and raises the price target fro...

 biolife-solns-q4-2024-adj-eps-002-beats-006-estimate

BioLife Solns (NASDAQ:BLFS) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.06)...

 biolife-solns-q4-sales-2271m-beat-2155m-estimate

BioLife Solns (NASDAQ:BLFS) reported quarterly sales of $22.71 million which beat the analyst consensus estimate of $21.55 mill...

 biolife-solutions-divests-freezer-units-reports-1007m-total-revenue-for-2024-exceeding-guidance-by-1-3-735m-from-cell-processing-184m-from-scisafe-and-87m-from-biostorage-services-including-evo-and-thaw

Reconciliation of Full Year 2024 Revenue Guidance to Preliminary Unaudited Revenue for Continuing OperationsDuring the fiscal y...

 biolife-solutions-reports-227m-q4-revenue-up-31-cell-processing-platform-up-37-evo-and-thaw-platform-down-8-full-year-revenue-at-823m-up-8-cell-processing-up-12-evo-and-thaw-down-14

Fourth quarter Cell Processing revenue increased 7% sequentially to $20.3 millionUnaudited revenue for FY2024 from Cell Process...

 northland-capital-markets-maintains-outperform-on-biolife-solns-raises-price-target-to-31

Northland Capital Markets analyst Carl Byrnes maintains BioLife Solns (NASDAQ:BLFS) with a Outperform and raises the price t...

 benchmark-reiterates-buy-on-biolife-solns-maintains-30-price-target

Benchmark analyst Robert Wasserman reiterates BioLife Solns (NASDAQ:BLFS) with a Buy and maintains $30 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION